Kymera Therapeutics (KYMR) Competitors $44.10 +1.51 (+3.55%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$43.54 -0.56 (-1.26%) As of 08/22/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR vs. ASND, RDY, QGEN, MRNA, BBIO, VRNA, ELAN, BPMC, ROIV, and GRFSShould you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Kymera Therapeutics vs. Its Competitors Ascendis Pharma A/S Dr. Reddy's Laboratories QIAGEN Moderna BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Roivant Sciences Grifols Ascendis Pharma A/S (NASDAQ:ASND) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk. Which has higher valuation and earnings, ASND or KYMR? Kymera Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$393.54M30.22-$409.12M-$5.16-37.66Kymera Therapeutics$44.71M70.52-$223.86M-$3.47-12.71 Does the media refer more to ASND or KYMR? In the previous week, Ascendis Pharma A/S had 1 more articles in the media than Kymera Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 9 mentions for Kymera Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.21 beat Kymera Therapeutics' score of 0.68 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ASND or KYMR more profitable? Ascendis Pharma A/S has a net margin of -54.94% compared to Kymera Therapeutics' net margin of -616.03%. Ascendis Pharma A/S's return on equity of 0.00% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-54.94% N/A -24.31% Kymera Therapeutics -616.03%-31.60%-27.12% Do analysts rate ASND or KYMR? Ascendis Pharma A/S currently has a consensus target price of $243.36, indicating a potential upside of 25.25%. Kymera Therapeutics has a consensus target price of $59.11, indicating a potential upside of 34.04%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 3.10 Which has more risk and volatility, ASND or KYMR? Ascendis Pharma A/S has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. SummaryKymera Therapeutics beats Ascendis Pharma A/S on 9 of the 15 factors compared between the two stocks. Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYMR vs. The Competition Export to ExcelMetricKymera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.05B$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-12.7120.8831.1026.04Price / Sales70.52343.33433.45102.77Price / CashN/A43.1937.7358.48Price / Book3.258.129.536.61Net Income-$223.86M-$54.72M$3.26B$265.56M7 Day Performance3.45%2.63%2.10%1.97%1 Month Performance-5.02%2.78%2.81%-0.36%1 Year Performance-7.70%11.01%30.56%19.03% Kymera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYMRKymera Therapeutics2.8849 of 5 stars$44.10+3.5%$59.11+34.0%-3.8%$3.05B$44.71M-12.71170ASNDAscendis Pharma A/S3.452 of 5 stars$194.08-2.1%$242.93+25.2%+39.4%$12.13B$490.75M-37.611,017News CoverageAnalyst ForecastRDYDr. Reddy's Laboratories3.1226 of 5 stars$14.26+0.2%$16.95+18.9%-12.1%$11.87B$3.81B21.6027,811News CoverageQGENQIAGEN3.827 of 5 stars$48.66-1.4%$49.69+2.1%+9.4%$10.97B$1.98B28.755,765MRNAModerna4.4344 of 5 stars$28.09+0.2%$43.59+55.2%-66.5%$10.90B$3.24B-3.735,800Analyst ForecastBBIOBridgeBio Pharma4.6808 of 5 stars$49.02-4.5%$61.35+25.2%+97.2%$9.81B$221.90M-11.99400Insider TradeVRNAVerona Pharma PLC American Depositary Share2.4253 of 5 stars$105.79+0.5%$109.00+3.0%+290.2%$8.96B$42.28M-106.8630Positive NewsShort Interest ↓ELANElanco Animal Health3.0971 of 5 stars$17.72-1.4%$17.33-2.2%+22.4%$8.92B$4.44B20.609,000Analyst DowngradeBPMCBlueprint Medicines0.4892 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences3.4485 of 5 stars$11.81-0.3%$16.50+39.7%+2.1%$8.06B$29.05M-16.87860Insider TradeGRFSGrifols3.5781 of 5 stars$10.58-1.3%$10.30-2.6%+14.8%$7.37B$7.45B9.0423,822Short Interest ↑ Related Companies and Tools Related Companies ASND Competitors RDY Competitors QGEN Competitors MRNA Competitors BBIO Competitors VRNA Competitors ELAN Competitors BPMC Competitors ROIV Competitors GRFS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYMR) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access